TearSolutions

TearSolutions is a private, pre-revenue biotech founded in 2021 and based in Charlottesville, Virginia, targeting the large and growing market for dry eye disease (DED) and ocular surface disease (OSD). Its core innovation is Lacripep, a synthetic peptide mimetic of the endogenous protein Lacritin, designed to address the underlying biological deficiency in OSD. The company has completed a positive Phase I/II trial in primary Sjögren's Syndrome and is preparing for a Phase IIb study in moderate/severe dry eye, positioning it in a competitive but high-need therapeutic area.

Peptide therapy platform based on Lacritin, a naturally occurring human tear protein that regulates basal tearing, epithelial health, and anti-inflammatory pathways. Lacripep is a synthetic peptide mimetic designed to restore Lacritin bioactivity.

The dry eye market is competitive, dominated by prescription drugs like Allergan's Restasis (cyclosporine) and Novartis's Xiidra (lifitegrast), alongside many OTC products. Lacripep competes by offering a distinct, physiology-restoring mechanism rather than pure immunosuppression, but must prove superior efficacy or faster onset in head-to-head trials to gain significant market share.